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Abstract
Objective. To create a tool to predict probability of remission and low disease activity (LDA) in patients
with RA being considered for anti-TNF treatment in clinical practice.
Methods. We analysed data from GO-MORE, an open-label, multinational, prospective study in biologic-
naı¨ve patients with active RA (DAS28-ESR53.2) despite DMARD therapy. Patients received 50 mg s.c.
golimumab (GLM) once monthly for 6 months. In secondary analyses, regression models were used to
determine the best set of baseline factors to predict remission (DAS28-ESR<2.6) at month 6 and LDA
(DAS28-ESR43.2) at month 1.
Results. In 3280 efficacy-evaluable patients, of 12 factors included in initial regression models predicting
remission or LDA, six were retained in final multivariable models. Greater likelihood of LDA and remission
was associated with being male; younger age; lower HAQ, ESR (or CRP) and tender joint count (or swollen
joint count) scores; and absence of comorbidities. In models predicting 1-, 3- and 6-month LDA or
remission, area under the receiver operating curve was 0.6480.809 (R2 =0.03970.1078). The models
also predicted 6-month HAQ and EuroQoL-5-dimension scores. A series of matrices were developed to
easily show predicted rates of remission and LDA.
Conclusion. A matrix tool was developed to show predicted GLM treatment outcomes in patients with
RA, based on a combination of six baseline characteristics. The tool could help provide practical guidance
in selection of candidates for anti-TNF therapy.
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Rheumatology key messages
. A regression model incorporating baseline characteristics predicted golimumab treatment outcomes in patients
with RA.
. A practical tool was developed to help select RA patients for anti-tumour necrosis factor therapy.
Introduction
To make best use of resources for biologic treatment in
patients with RA, it would be useful to identify a set of
predictors that enable selection of patients who will benefit
most from such treatment and avoid treatment of patients
who are unlikely to respond. Several studies have evalu-
ated predictors of outcomes during anti-TNF treatment (for
a review, see [1, 2]). One limitation of some of these studies
[3] is that the predictive capacity of single predictors is low
(vs combinations of predictors), and they are less useful
when making practice decisions for individual patients.
Although there is variability in which factors have pre-
dictive ability, some of the baseline characteristics that
have been found to predict anti-TNF outcomes include
baseline age (e.g. [4, 5]), smoking (e.g. [68]), gender
(e.g. [6, 9]), disease activity (e.g. [10, 11]) and functional
ability (e.g. [4]). Predictors that are significant across stu-
dies may depend on factors such as the patient popula-
tion, type of treatment, the outcome being evaluated and
whether the outcome is a state measure or an improve-
ment measure.
Current EULAR recommendations emphasize low dis-
ease activity (LDA) or remission as the treatment goal in
RA and advocate the use of poor prognostic factors to
guide treatment decisions [12]. If a patient does not
attain remission or LDA with DMARDs and if poor prog-
nostic factors are present (e.g. high disease activity, RF
positivity and CCP antibodies, erosive disease), EULAR
recommendations suggest the addition of a biologic treat-
ment. However, poor prognostic factors such as high
baseline disease activity have also been shown to be
associated with poorer anti-TNF treatment outcomes;
that is, patients who begin anti-TNF treatment with high
disease activity have been reported to be less likely to
achieve remission or LDA than patients who begin treat-
ment with more moderate disease activity (e.g. [11, 13]).
This adds complexity to clinical decisions balancing risks
and benefits to determine which patients will benefit most
from anti-TNF treatment.
The goal of these analyses was to develop a tool that
can be used to assist in decision making to optimize treat-
ment goal attainment in patients with RA who have failed
DMARD treatment. The tool identifies groups of patients
who would most likely benefit from golimumab (GLM)
therapy and presents findings in a form that is simple
and can be used in daily clinical practice.
Methods
Design and patients
Analysis of associations between baseline characteristics
and outcomes of treatment was a key secondary
objective of the GO-MORE trial. GO-MORE was an
open-label, prospective study of add-on treatment with
GLM in patients with active RA despite DMARD treatment
in 40 countries (protocol P06129; NCT00975130). Details
of the study procedures have been previously reported
[13] and are only briefly described here. The GO-MORE
study received approval from appropriate research ethics
committees in each country and was conducted in ac-
cordance with the Declaration of Helsinki and standards
of good clinical research practice. All patients consented
to participate in the GO-MORE study. The analysis for this
study did not require a separate approval. Data were col-
lected from 29 October 2009 to 21 July 2011. Patients in
GO-MORE were biologic-naı¨ve with active RA (DAS28-
ESR53.2) despite DMARD therapy and had no contra-
indications for TNF inhibitor treatment.
Study procedures
In the first 6 months of GO-MORE, all patients received
monthly s.c. GLM 50 mg administered by autoinjector and
had efficacy and safety assessments at months 1, 3 and
6. At month 6, patients who had good or moderate EULAR
response but were not in remission were able to continue
to part 2 of the study, an extension phase that is
described in length elsewhere [13].
Statistical analyses
A sequence of steps was used to develop an optimal
model to predict remission. The main outcomes to be
predicted were DAS28-ESR LDA at the end of month 1
(after one injection) and remission at the end of month 6.
The model’s ability to predict DAS28-ESR remission,
DAS28-ESR LDA, Simple Disease Activity Index (SDAI)
remission (SDAI43.3) and LDA (SDAI411 = LDA), and
DAS28 based on CRP (cut-off criteria:<2.6 and43.2) at
different time points during treatment was also explored.
Baseline predictors included in the initial univariate ana-
lyses were gender, age, disease duration, smoking status,
comorbidities, number of previously failed DMARDs, 28-
joint tender joint count (TJC28), 28-joint swollen joint
count (SJC28), patient global assessment of disease ac-
tivity (measured on a 100-mm visual analogue scale), HAQ
score, MTX dose and log ESR. Characteristics that pre-
dicted DAS28-ESR remission at month 6 and LDA at
month 1 at the P< 0.10 level were retained and used in
multivariable models. Stepwise selection was used as a
sensitivity analysis to confirm the factors selected for the
model.
To determine whether TJC and SJC or ESR and CRP
could be used interchangeably with no loss in predictive
power, multivariable models switching out these compo-
nents were compared. Area under the receiver operating
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characteristic curve (AUC-ROC) analysis and R2 were
used to evaluate the models.
To create the matrix tool, continuous variables were
transformed to categorical variables, using tertiles or
quartiles. Models with three- and four-level categories
were evaluated using AUC-ROC analysis. The predicted
LDA/remission rates were displayed in an easily readable
colour-coded matrix.
Additional analyses were performed to explore the
model’s usefulness and limitations. For these additional
analyses, patients were divided into subgroups of
DAS28 predicted remission at 6 months (patients pre-
dicted to have<10% chance of DAS28 remission, 10 to
<20%, 20 to< 30%, 30 to <40%, 40 to< 50% and
550% chance of DAS28 remission). First, the associ-
ations between the predictors and outcomes of physical
function (HAQ) and quality of life [EuroQol-5-dimension
(EQ-5)] were explored. For patients in each prediction
subgroup, median and interquartile ranges for DAS28,
HAQ and EQ-5D at baseline and 6 months and the
change in value from baseline to 6 months were calcu-
lated. Next, the association between the predictors and
DAS28 improvement (as opposed to DAS28 disease
state) over 6 months was investigated. Finally, the asso-
ciations between the predictors and EULAR response and
the associations between the predictors and ACR criteria
for response were evaluated.
Results
Disposition and baseline characteristics
Of 3366 patients enrolled in GO-MORE, 3280 were
included in the efficacy evaluable population. The patient
disposition and baseline characteristics are fully reported
in [13]. A summary of baseline characteristics is shown in
Table 1. A majority of patients were female (82.8%, 2716/
3280) and the mean (S.D.) age was 52.3 (12.8) years. A
majority of patients 78.7% (2572/3280) had high disease
activity (DAS28-ESR>5.1) at baseline; the remaining pa-
tients had moderate disease activity (DAS28-ESR of
3.25.1) at baseline. At least one comorbidity was re-
ported by 76.2% of patients (2499/3280). See supplemen-
tary Table S1, available at Rheumatology Online, for a list
of the comorbidities that were reported in52% of
patients.
Regression model for prediction of remission and LDA
At the end of month 6, 23.9% of patients had achieved
DAS28-ESR remission and 37.4% achieved LDA; at the
end of month 1, 16.6% of patients had achieved LDA [13].
Initial univariate analyses narrowed the set of factors that
were candidates for the multivariable models predicting
remission and LDA. Factors retained [those that had sig-
nificant relationships (P< 0.10) with DAS28 remission at
month 6 and LDA at month 1] were analysed in a multi-
variable model predicting DAS28-ESR remission at month
6 (supplementary Table S2, available at Rheumatology
Online). Factors retained after this step were gender,
HAQ, presence of comorbidities, age, TJC and ESR.
Smoking was associated with remission at 6 months but
not with LDA at 1 month, and therefore was not retained.
Overall, the predictive value of the model (Table 2) was
slightly weakened by replacing TJC with SJC or by repla-
cing CRP with ESR in the models predicting DAS28. The
pattern of results was similar for models predicting SDAI
and DAS28-CRP outcomes at months 1, 3 and 6.
Prediction of outcomes at month 1 was slightly better
than for outcomes at month 6.
To translate the data into the prediction matrix tool,
continuous predictor variables (age, ESR and TJC) had
to be transformed to categorical variables with either
three or four levels. AUC and R2 values for models with
the continuous vs categorical variables indicated that little
predictive power was lost moving from continuous to cat-
egorical variables (data not shown). Categorical variables
with three levels were selected for all but age because this
resulted in a simpler matrix tool.
Prediction matrix tool
Predicted remission and LDA rates from the final multi-
variable models were used to create a series of matrix
TABLE 1 Demographics and baseline characteristics of
patients in the efficacy population of GO-MORE
Patient characteristics n=3280
Demographic characteristics
Female, n (%) 2716 (82.8)
Age, median (min, max), years 53.0 (18, 88)
Disease characteristics
Disease duration, years n = 3279
Median (min, max) 4.9 (0.01, 56.6)
TJC28, mean (S.D.) 13.0 (6.81)
SJC28, mean (S.D.) 9.6 (5.56)
DAS28-ESR n = 3270
Moderate disease activity
(3.25.1), n (%)
698 (21.3)
High disease activity
(>5.1), n (%)
2572 (78.7)
Mean (S.D.) 5.97 (1.095)
DAS28-CRP n = 3236
Mean (SD) 5.41 (0.998)
CRP, mg/l n = 3236
Mean (S.D.) 14.48 (20.376)
ESR, mm/h n = 3280
Mean (S.D.) 34.9 (24.64)
Anti-CCP n = 3225
Positive (520 U/ml), n (%) 2318 (71.9)
RF n = 3234
Positive (515 IU/ml), n (%) 2344 (72.5)
HAQ-DI, mean (S.D.) 1.44 (0.67)
Table adapted from Combe B, Dasgupta B, Louw I, et al.
Efficacy and safety of golimumab as add-on therapy to dis-
ease-modifying antirheumatic drugs: results of the GO-
MORE study. Ann Rheum Dis 2014;73:147786 [13]. with
permission ! (2004) BMJ publishing group. SJC28: joint
swollen joint count 28; TJC28, joint tender joint count 28;
n: number.
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tools, as shown in Fig. 1 and supplementary Fig. S1, avail-
able at Rheumatology Online. Figures for males and fe-
males were generated separately (the impact of each
predictor was similar in each gender group, but males
had better outcomes overall). Separate models were gen-
erated to predict DAS28 remission and LDA, and for SDAI
remission and LDA. In addition, separate models were
created for use with ESR vs CRP as the inflammatory
marker.
Each matrix shows the predicted remission or LDA rate
for every combination of the six baseline factors, repre-
senting a total of 432 different RA subpopulations. Across
all models, the highest remission rates are in the cells at
the upper right and the lowest rates in the cells at the
lower left. The colour codes have been added for easier
visual perception of the matrix, with each colour repre-
senting an estimated range of 10% likelihood of remission
or LDA; warmer colours (e.g. red, yellow) indicate worse
predicted outcomes and cooler colours (e.g. blue, purple)
indicate better predicted outcomes. Odds ratios (ORs)
associated with each factor are shown in Table 3. Low
baseline TJC and ESR were the strongest predictors in
the model. In addition, higher remission rates are pre-
dicted for patients who are male, have no comorbidities,
are younger in age and have lower baseline HAQ.
Additional analyses to explore the matrix model’s
usefulness and limitations
The factors in the model built to predict DAS28 remission
or LDA also were associated with attainment of meaning-
ful EQ-5D and HAQ cut-offs (supplementary Table S3,
available at Rheumatology Online). Of all the factors
included in the model, baseline HAQ was most strongly
related to attainment of cut-off levels for EQ-5D (50.7
and50.8) and HAQ (<0.5) at month 6 (ORs from 2.38 to
6.55 for the lowest vs highest HAQ score categories).
In Fig. 2, patients are divided by their predicted rate of
remission from the matrix tool, which is determined by their
baseline characteristics. For each category of predicted
remission (e.g. patients with 10% predicted rate of remis-
sion, shown in red in both the matrix model and Fig. 2), the
median and interquartile range for baseline and month 6
DAS28-ESR are shown. The data reveal that patients who
were predicted to have the lowest chance of remission (i.e.
those in the<10% group; the red line in the figure, who also
have the highest disease activity at baseline) also had the
greatest change in DAS28-ESR score between baseline
and month 6 (Fig. 2A). That is, the patients who had the
worst values for their predictors improved the most and yet
were still the least likely to attain remission. A similar pat-
tern was seen for HAQ and EQ-5D scores (Fig. 2B and C).
Figure 3 shows the relationship between the categories
of predicted response rates derived from the matrix model
and the actual month 6 attainment of EULAR response
and ACR20, ACR50 and ACR70 response. EULAR re-
sponse is a measure of both disease state and improve-
ment over time, and it was not related to the predicted
probability of remission. EULAR response was about
82%, regardless of the rate of remission predicted by
the matrix tool. Similarly, no differences in ACR20 re-
sponse rates were observed across different probabilities
of remission; however, ACR50 and ACR70 response rates
TABLE 2 Prediction of multiple disease activity outcomes with three different sets of baseline factors
Outcome predicted Baseline predictor seta
Month 1 Month 3 Month 6
AUC R2 AUC R2 AUC R2
DAS28-ESR remission With TJC, ESR 0.809 0.0954 0.738 0.1002 0.717 0.1078
With SJC, CRP 0.729 0.0521 0.694 0.0696 0.687 0.0815
With TJC, CRP 0.758 0.0660 0.707 0.0788 0.702 0.0949
DAS28-ESR LDA With TJC, ESR 0.795 0.1565 0.734 0.1372 0.710 0.1261
With SJC, CRP 0.724 0.0937 0.682 0.0874 0.665 0.0807
With TJC, CRP 0.757 0.1202 0.702 0.1057 0.690 0.1052
SDAI remission With TJC, ESR 0.708 0.0168 0.664 0.0282 0.655 0.0394
With SJC, CRP 0.703 0.0153 0.648 0.0226 0.648 0.0353
With TJC, CRP 0.706 0.0158 0.663 0.0288 0.658 0.0409
SDAI LDA With TJC, ESR 0.707 0.0145 0.661 0.0266 0.660 0.0397
With SJC, CRP 0.705 0.0144 0.649 0.0224 0.651 0.0352
With TJC, CRP 0.701 0.0142 0.662 0.0281 0.664 0.0418
DAS28-CRP <2.6 With TJC, ESR 0.738 0.0777 0.687 0.0785 0.674 0.0820
With SJC, CRP 0.698 0.0536 0.658 0.0570 0.661 0.0711
With TJC, CRP 0.737 0.0780 0.687 0.0795 0.683 0.0924
DAS28-CRP 43.2 With TJC, ESR 0.751 0.1448 0.700 0.1152 0.683 0.0995
With SJC, CRP 0.712 0.1063 0.681 0.0954 0.661 0.0791
With TJC, CRP 0.753 0.1473 0.705 0.1209 0.689 0.1071
aAll factor sets include continuous HAQ and categorical gender and comorbidity. Inclusion of ESR, CRP, TJC and SJC varied
as indicated. TJC, SJC, ESR and CRP were all continuous variables. CRP was used in logarithm scale. AUC: area under the
curve; LDA: low disease activity; SDAI: Simple Disease Activity Index; SJC: swollen joint count; TJC: tender joint count.
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FIG. 1 Matrix tool predicting outcomes of golimumab treatment at month 6
The model estimates outcomes at month 6 for each combination of predictor variables. Predicted rates shown for
DAS28-ESR remission in female (A) and male (B) patients at 6 months, DAS28-ESR LDA in female patients at 6 months
(C), and SDAI low disease activity in female patients using CRP instead of ESR as a predictor at 6 months (D). LDA: low
disease activity; SDAI: Simple Disease Activity Index.
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FIG. 1 Continued
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increased in patients with a higher predicted probability of
remission (both P< 0.01).
Discussion
Tools that determine which patients with RA might benefit
from biologic treatment can help in making value-based
decisions. We have developed a tool derived from data
collected in a large trial of GLM treatment in more than
3000 patients with active RA despite DMARD treatment.
The matrix tool predicts outcomes of 432 subpopulations
of patients with RA identified by combinations of six char-
acteristics (gender, HAQ, presence of comorbidities, age,
TJC and ESR) that are associated with LDA and remission
in the early treatment phase. The value of the model was
not weakened by replacing ESR with CRP, which may be
the preferred marker of inflammation used in clinical prac-
tice. It can assist clinicians in identification of patients for
treatment, aid in establishing a treatment goal for an indi-
vidual patient and provide guidance to policy-makers for
the selection of RA patient populations that are likely to
achieve good disease states from anti-TNF treatment. The
model can be used to predict outcomes at several time
points during treatment, and the predictions for disease
activity are also relevant to physical function and quality of
life outcomes. A similar matrix model approach to visua-
lizing prediction of remission and response has been de-
veloped for patients with AS treated with biologics [14].
The data are important when considering the implica-
tions of treatment recommendations and reimbursement
criteria on both patient selection criteria and patient out-
comes as patients are considered for anti-TNF treatment.
TABLE 3 Odds ratios for associations of individual predictor variables with DAS28-ESR remission and LDA at months
1, 3 and 6
OR (95% CI)
Variable Month 1 Month 3 Month 6
DAS28-ESR remission
ESR
<15 vs 545 9.18 (5.62, 15.01) 4.71 (3.45, 6.42) 3.43 (2.66, 4.41)
515 to<45 vs 545 2.62 (1.60, 4.29) 2.20 (1.64, 2.94) 1.68 (1.33, 2.11)
Gender
Male vs female 1.58 (1.16, 2.15) 1.73 (1.37, 2.19) 1.64 (1.33, 2.02)
HAQ
0 to 1.125 vs 51.75 1.70 (1.18, 2.45) 1.40 (1.09, 1.80) 1.79 (1.44, 2.22)
51.125 to< 1.75 vs 51.75 1.48 (0.99, 2.19) 1.19 (0.91, 1.56) 1.20 (0.95, 1.51)
Age, years
<35 vs 565 1.71 (1.02, 2.87) 2.00 (1.33, 2.99) 1.92 (1.35, 2.73)
535 to<50 vs 565 1.15 (0.74, 1.78) 1.59 (1.14, 2.21) 1.54 (1.16, 2.04)
550 to<65 vs 565 0.88 (0.57, 1.34) 1.23 (0.90, 1.70) 1.14 (0.88, 1.49)
Comorbidities
No vs yes 1.51 (1.11, 2.04) 1.44 (1.15, 1.81) 1.34 (1.10, 1.65)
TJC
<10 vs 520 5.12 (2.92, 9.00) 2.81 (2.02, 3.92) 2.87 (2.14, 3.84)
510 to<20 vs 520 2.09 (1.18, 3.70) 1.43 (1.03, 1.99) 1.85 (1.39, 2.45)
DAS28-ESR low disease activity
ESR
<15 vs 545 5.92 (4.32, 8.11) 4.35 (3.40, 5.55) 3.34 (2.67, 4.18)
515 to<45 vs 545 2.13 (1.58, 2.87) 1.78 (1.44, 2.21) 1.67 (1.38, 2.02)
Gender
Male vs female 1.65 (1.30, 2.10) 1.46 (1.18, 1.80) 1.44 (1.18, 1.76)
HAQB
0 to 1.125 vs 51.75 1.79 (1.38, 2.32) 1.59 (1.30, 1.96) 1.68 (1.39, 2.03)
51.125 to< 1.75 vs 51.75 1.34 (1.01, 1.79) 1.25 (1.00, 1.56) 1.16 (0.95, 1.41)
Age, years
<35 vs 565 1.58 (1.07, 2.33) 1.47 (1.05, 2.06) 1.65 (1.20, 2.26)
535 to<50 vs 565 1.07 (0.78, 1.46) 1.24 (0.96, 1.61) 1.27 (1.00, 1.62)
550 to<65 vs 565 0.82 (0.61, 1.11) 1.02 (0.80, 1.30) 1.07 (0.86, 1.34)
Comorbidities
No vs yes 1.49 (1.18, 1.89) 1.36 (1.11, 1.65) 1.15 (0.95, 1.39)
TJC
<10 vs 520 6.13 (4.13, 9.08) 3.65 (2.77, 4.81) 3.35 (2.62, 4.28)
510 to<20 vs 520 2.04 (1.37, 3.03) 1.85 (1.42, 2.42) 1.85 (1.46, 2.33)
EQ-5D: EuroQol 5-dimension; HAQB: health assessment questionnaire at baseline; LDA: low disease activity; OR: odds ratio;
TJC: tender joint count.
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FIG. 2 Relationship between predicted remission rate and other outcomes in the GO-MORE study
The figure shows the relationship between the remission rate category predicted by the matrix model and the observed
median DAS28 (A), EQ-5D (B) and HAQ (C) scores in the GO-MORE study. Figure 2A shows, for example, that for the
patients who were predicted by the matrix tool to have a remission rate of< 10% (red line), the actual median DAS28
score at baseline was 7.34, with median improvement of 2.61 at month 6. For patients predicted by the matrix tool to
have 550% remission rate (blue line), their median baseline DAS28 ESR score was 4.36, with median improvement of
1.84 at month 6. The vertical line indicates the interquartile range. Note that improvement is positive change for EQ-5D;
improvement is negative change for DAS28 and HAQ.: median change. EQ-5D, EuroQol 5-dimension; IQR, interquartile
range.
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For example, in the UK, reimbursement for biologic treat-
ment in RA is limited to patients who have a DAS28>5.1.
In Belgium, the threshold for reimbursement is
DAS28>3.7. The GO-MORE study included patients
from both of these countries, and we compared treatment
efficacy based on these eligibility criteria. For patients
from the UK, 185/263 (70%) had DAS28-ESR>5.1 at
baseline. For patients from Belgium, 114/123 (93%) had
DAS28-ESR>3.7. In these subgroups of patients who
would have been eligible for reimbursement, the selection
criterion based on DAS28 led to large differences in the
HAQ score, ESR and SJC of selected patients at baseline.
As a result, remission was obtained by 20% of UK pa-
tients and 43% of Belgian patients. LDA was obtained
by 35% of UK patients and 55% of Belgian patients. In
this analysis, because of different policy regarding access
to treatment in the UK and Belgium, the Belgian popula-
tion had a doubled rate of remission.
Although patients with lower baseline disease activity
were more likely to achieve remission and LDA, patients
with high baseline disease activity demonstrated greater
improvement in their DAS28, HAQ and EQ5D scores. The
differences in remission rates and improvement rates in the
different subpopulations counterbalanced each other and
resulted in nearly equal EULAR response rates across the
population (Fig. 3A). This may suggest that, at least for
some DMARD refractory populations, response is a more
appropriate goal of treatment than LDA or remission. At the
same time, the excellent remission rates that can be ob-
tained in patients with moderate disease activity, combined
with ACR50 and ACR70 response rates (which are greater
than those in patients with high disease activity), may be a
convincing argument to open up that patient population for
treatment in countries such as the UK.
Health Technology Assessments tend to be based on
change-scores between two treatments compared in
randomized, controlled trials and resulting in cost of qual-
ity-adjusted life-years. However, when clinicians make
treatment choices or adjustments to treatments, they
tend to rely on disease state rather than level of improve-
ment. Elevated disease activity in patients with RA receiv-
ing anti-TNF treatment is associated with dose increases
[15], and also the other direct and indirect costs of care of
patients with RA are significantly lower in patients with
LDA or remission as opposed to those who have moder-
ate or high disease activity [16, 17]. Physical function, and
to a lesser extent disease activity state, have been shown
to be the major drivers of cost of RA management.
Supplementary Tables S4 and S5, available at
Rheumatology Online, summarize cost associated with
different levels of HAQ, DAS28 and SDAI, and indicate
that, even for biologic-treated patients, function and dis-
ease activity drive health care utilization costs of patients
maintained on treatment. Therefore, not only the cost
associated with change of disease state but also the dis-
ease state that is achieved is of importance for value-
based decision making. Once the decision to treat is
made, the eventual disease state achieved will be the
driver of cost and further decision making. This may be
an argument to value achievement of good disease state
FIG. 3 Relationship between predicted DAS28-ESR remission rate and EULAR response (A), ACR20 (B), ACR50 (C) and
ACR70 (D)
For each category of predicted DAS28-ESR remission rate from the matrix model, the figure shows the percentage of
patients who attained good or moderate EULAR response after 6 months of GLM treatment. GLM: golimumab.
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more than improvement. Another consideration for payers
is that cost of treatment may be reduced if patients, as per
EULAR recommendations, can taper or stop therapy after
achieving sustained remission (EULAR recommendation
12) [12]. Better selection of patients who are likely to
achieve remission may increase the likelihood of tapering
or stopping therapy. Early achievement of remission ap-
pears to be an important component to successfully stop-
ping therapy, which points to the relevance of the 1- and
3-month time points we chose for prediction of disease
state in our analysis [18].
Most of the factors included in the matrix model are
validated by a number of studies that have analysed indi-
vidual predictors of RA treatment outcomes in studies of
other biologics [1, 2], thereby increasing the face-validity of
the model. Some characteristics, such as smoking, were
not predictive in this dataset, but may be predictors in the
overall RA population. The presence of comorbidities as a
prognostic indicator has been shown previously [19], and it
has also been shown that greater comorbidity is associated
with greater physical disability in patients with RA [3].
Because collection of comorbidity data in GO-MORE was
not rigorous, and comorbidities were likely to have been
underreported in this study, future work should further ex-
plore the nature of the relationship between comorbidities
and RA outcomes. In addition to the effect of comorbidities
on outcomes, presence of certain serious comorbid dis-
eases may considerably affect the treatment decision.
Further research will be helpful to validate this model in
other populations, improve its predictive ability or expand
its usefulness to include prediction of other outcomes.
Although AUC in the ROC analysis of the prediction
models was relatively high, not all factors that may
affect response were included in the model. For example,
patient expectations about effectiveness of treatment
have been shown to be associated with remission [20].
The very large patient numbers are a clear strength of
this analysis. A weakness of this model, however, is that
the non-randomized nature of the study does not allow a
direct comparison with patients who are not receiving an
anti-TNF agent (e.g. in a placebo-controlled study) or are
treated with an alternative medicine (e.g. DMARD combin-
ation therapy or a biologic with another mode of action).
Although our model clearly highlights which RA subpopu-
lations benefit more than other subpopulations during
treatment with GLM, it does not address whether GLM
is better than an alternative treatment strategy. Similar
analyses in randomized studies could determine which
treatment strategy is optimal in patient groups with char-
acteristics that predicted the poorest outcomes in our
study, such as older-aged female patients with high dis-
ease activity, severe disability and comorbidities.
Conclusion
A matrix tool was developed to predict GLM treatment
outcomes in patients with RA, based on a combination
of six baseline demographic and disease characteristics
of patients. Value of the outcome of therapy may be the
amount of improvement in disease activity or the eventual
disease state achieved. It is expected that such a tool will
assist physicians, guideline committees and payers in
providing practical guidance on identification and selec-
tion of appropriate candidates for anti-TNF therapy.
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